Advanced Solid Tumor Clinical Trials in Chicago, Illinois

15 studies are recruiting for advanced solid tumor in Chicago, Illinois right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

   This is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced unresectable or metastatic solid tumors. The study is enrolling cohorts of participants with melanoma [cutaneous/acral], squamous cell carcinomas of the head and neck (SCCHN), HER2-negative gastric can…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of Illinois Cancer Center, Chicago, Illinois

   Locations

   90 in total

   Run by

   Daiichi Sankyo

   See if you can join NCT06172478 on ClinicalTrials.gov

2. Study of ISM6331 in Participants With Advanced/Metastatic Mesothelioma or Other Advanced Solid Tumors

   This is a Phase 1/2, open-label, multicenter, FIH study to evaluate the safety, tolerability, recommended Phase 2 dose (RP2D), PK/PD, and preliminary anti-tumor activity of ISM6331 in participants with advanced or metastatic mesothelioma or other Advanced solid tumors. The study consists of two par…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   The University of Chicago Medical Center - Duchossois Center for Advanced Medicine, Chicago, Illinois

   Locations

   10 in total

   Run by

   InSilico Medicine Hong Kong Limited

   See if you can join NCT06566079 on ClinicalTrials.gov

3. A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

   The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Chicago Hospital, Chicago, Illinois

   Locations

   39 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT06465069 on ClinicalTrials.gov

4. Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion

   This is a Phase 1, open-label, multicenter, study of the safety, tolerability, PK, PD, and anti-tumor activity of MRTX1719 patients with advanced, unresectable or metastatic solid tumor malignancy with homozygous deletion of the MTAP gene.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Local Institution - 124, Chicago, Illinois

   Locations

   25 in total

   Run by

   Bristol-Myers Squibb

   See if you can join NCT05245500 on ClinicalTrials.gov

5. A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

   The purpose of this open-label, first-in-human (FIH) trial is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of DZR123 (Tulmimetostat, CPI-0209), both as monotherapy and in combination with enzalutamide, in patients with advanced solid t…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Chicago Medical Center, Chicago, Illinois

   Locations

   80 in total

   Run by

   Novartis Pharmaceuticals

   See if you can join NCT04104776 on ClinicalTrials.gov

6. Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors

   BIPAVE-001 is a Phase 1-2 study for evaluating the safety, pharmacokinetics (PK), and efficacy of AI-081 in solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Northwestern University, Chicago, Illinois

   Locations

   21 in total

   Run by

   OncoC4, Inc.

   See if you can join NCT06635785 on ClinicalTrials.gov

7. Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers

   This is a phase 1/2, multicenter, open-label study. The phase 1 portion is a dose escalation and expansion study of STK-012 as monotherapy and in combination therapy in patients with selected advanced solid tumors. The phase 2 portion is a randomized study of STK-012 in combination with standard of…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Chicago, Chicago, Illinois

   Locations

   47 in total

   Run by

   Synthekine

   See if you can join NCT05098132 on ClinicalTrials.gov

8. A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers

   This is a multi-center, first-in-human, open label, dose escalation (Part A) and expansion (Part B) Phase 1 study in subjects with advanced solid tumors and in subjects with solid tumors with selected genetic alterations that are either direct (YES1 amplification) or dependent (Hippo Pathway altera…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Chicago, Chicago, Illinois

   Locations

   15 in total

   Run by

   Nuvectis Pharma, Inc.

   See if you can join NCT05873686 on ClinicalTrials.gov

9. A Study of PYX-201 in Advanced Solid Tumors

   The primary objectives of this study are to determine the recommended dose(s) of PYX-201 for participants with recurrent/metastatic (R/M) solid tumors, and to determine the objective response rate (ORR) in participants treated with PYX-201 as a single agent.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Chicago Medicine, Chicago, Illinois

   Locations

   29 in total

   Run by

   Pyxis Oncology, Inc

   See if you can join NCT05720117 on ClinicalTrials.gov

10. Evaluating Personalized Therapeutics Clinic (PTC) on Drug-Drug Interactions and Drug-Gene Interactions

    The purpose of this study is to determine whether a consultation with a Personalized Therapeutics Clinic, or PTC, will help participants lower the risk for side effects (drug-drug interactions and drug-gene interactions) when taking many medications and help providers improve prescribing decisions …

    Stage

    Not phased

    Ages

    18 and older

    Site

    University of Chicago Medicine, Chicago, Illinois

    Run by

    University of Chicago

    See if you can join NCT05166694 on ClinicalTrials.gov

11. STM-06: POLARIS-POlymetastic Lesion Ablative Radiotherapy With Immunotherapy Study

    This is a non-randomized two-arm trial, specifically a pilot study in which patients with advanced solid tumor cancer with 3-10 metastatic lesions who are on immunotherapy will receive ablative RT to up to 10 lesions. After study intervention, participants will undergo ctDNA collection at 8 weeks a…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Illinois at Chicago, Chicago, Illinois

    Run by

    University of Illinois at Chicago

    See if you can join NCT07269080 on ClinicalTrials.gov

12. A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

    Phase 1 dose escalation and expansion study of CLSP-1025, a first-in-class HLA-A*02:01 specific T cell engager (TCE) targeting solid tumors that harbor the p53 R175H mutation.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    The University of Chicago Comprehensive Cancer Center, Chicago, Illinois

    Locations

    21 in total

    Run by

    Clasp Therapeutics, Inc.

    See if you can join NCT06778863 on ClinicalTrials.gov

13. FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors

    This is a phase 1 study designed to evaluate the safety, tolerability, and antitumor activity of FT825 (also known as ONO-8250) with or without monoclonal antibody therapy following chemotherapy in participants with advanced human epidermal growth factor receptor 2 (HER2)-positive or other advanced…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Chicago Medical Center, Chicago, Illinois

    Locations

    14 in total

    Run by

    Fate Therapeutics

    See if you can join NCT06241456 on ClinicalTrials.gov

14. Study of SGR-3515 In Participants With Advanced Solid Tumors.

    The purpose of this study is to learn about the effects of a new study drug, called SGR-3515 that may be a treatment for advanced solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Northwestern University, Chicago, Illinois

    Locations

    14 in total

    Run by

    Schrödinger, Inc.

    See if you can join NCT06463340 on ClinicalTrials.gov

15. A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors

    This is a Phase 2, multi center, open-label study to evaluate the safety and efficacy of Type II RAF (tovorafenib) in pediatric participants with low-grade glioma or advanced solid tumors. Qualifying genomic alterations will be identified through molecular assays as routinely performed at Clinical …

    Stage

    Phase 2

    Ages

    0 to 25

    Site

    Lurie Children's Hospital of Chicago, Chicago, Illinois

    Locations

    35 in total

    Run by

    Day One Biopharmaceuticals, Inc.

    See if you can join NCT04775485 on ClinicalTrials.gov